Date: 2014-10-06
Type of information: IPO
Company: VBL Therapeutics (Israel)
Investors:
Amount: $34.4 million (€ 27.5 million)
Funding type: IPO
Planned used: The proceeds from the offering are expected to enable the advancement of the company\'s development plan in both its Vascular Targeting System® and Lecinoxoid platform technologies through the end of 2016.
Others: * On October 6, 2014, VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, announced the closing of its initial public offering of 6,666,667 shares of its common stock at a public offering price of $6.00 share, before underwriting discounts and commissions. As a result, aggregate net proceeds to the Company, after underwriting discounts and commissions and other estimated offering expenses, will be approximately $34.4 million. As previously reported, VBL Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,000,000 ordinary shares to cover over-allotments, if any, at the initial public offering price, before underwriting discounts and commissions. * On September 30, 2014, VBL Therapeutics announced the pricing of its initial public offering of 6,666,667 of its ordinary shares at a public offering price of $6.00 per share, before underwriting discounts and commissions. In addition, VBL Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,000,000 ordinary shares at the same price, less underwriting discounts and commissions, to cover over-allotments, if any. The shares are scheduled to begin trading on the NASDAQ Global Market on October 1, 2014 under the ticker symbol \"VBLT.\" The offering is expected to close on October 6, 2014, subject to customary closing conditions. Deutsche Bank Securities is acting as book-running manager for the offering. JMP Securities and Oppenheimer & Co. are acting as co-managers.
Therapeutic area: Cancer - Oncology - Immunological diseases - Inflammatory diseases
